Arca
Skip to content
Tools
Tools

Selegiline HCL Tablets USP 5mg

Recall D-1479-2016, part of FDA recall event 75025. See Stason Pharmaceuticals's company page.

Stason Pharmaceuticals, Inc. started this Class III drug recall on Aug 23, 2016 (voluntary: firm initiated); FDA lists it as terminated, terminated Oct 23, 2017.

  • Classification: Class III
  • Started: Aug 23, 2016
  • Status: Terminated

Why It Was Recalled

Class III

Stason Pharmaceuticals is recalling Selegiline HCl tablets, USP 5mg 60 count bottle due to an out of specification result for dissolution of stability samples.

Record

Product
Selegiline HCL Tablets USP 5mg, 60- count bottles, Rx only, Manufactured by: Stason Pharmaceuticals, Inc. Irvine, CA 92618 Distributed by: Libertas Pharma, Inc. Montgomery, AL 36117. NDC 51862-146-06
Quantity
17,013 units
Lots and codes
Lot #: 14F030, 14F031, 14F032, Exp. June 2017; 15G022, Exp. July 2018
Distribution
North Carolina
Recalling firm
Stason Pharmaceuticals, Inc., Irvine, CA, United States
How the firm notified
Letter
FDA classified
Sep 2, 2016

Stason Pharmaceuticals, Inc.'s Other Recalls

Newest first, one product per recall event; search them all

FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.